Table 2.
Variable | Reference value | HF patients (n= 35) | |||
---|---|---|---|---|---|
Pre-LVAD (n = 35) | Post-LVAD (n = 35) | ||||
| |||||
I | II | III | IV | ||
| |||||
Non-bleeder group (n = 13) | Bleeder group (n = 22) | Non-bleeder group (n = 13) | Bleeder group (n = 22) | ||
Leukocytes (×103/μL) | 4.5–11.0 | 7.94 ± 3.11 | 8.03 ± 2.84 | 10.87 ± 3.10a | 11.04 ± 2.95b |
Erythrocytes (×106/μL) | 4.0–5.7 | 4.34 ± 1.12 | 4.06 ± 1.10 | 3.21 ± 0.97 a | 2.14 ± 0.57b,c |
Platelet (×103/μL) | 153–367 | 202.70 ± 71.70 | 207.23 ± 73.99 | 309 ± 215.05 | 231.50 ±121.96 |
Hemoglobin (g/dL) | 12.6–17.4 | 10.75 ± 2.34 | 10.24 ± 1.71 | 9.03 ± 1.02 a | 8.39 ± 0.78b,c |
Hematocrit (%) | 37–50 | 35.15 ± 7.59 | 34.68 ± 8.37 | 29.08 ± 3.11a | 27.72 ± 2.35b |
BUN (mg/dL) | 9–20 | 28.35 ± 8.94 | 30.48 ± 10.31 | 37.46 ± 13.61 | 50.37 ± 19.82b,c |
Creatinine (mg/dL) | 0.66–1.25 | 1.41 ± 0.83 | 1.44 ± 0.58 | 1.59 ± 1.01 | 1.09 ± 0.23b,c |
Total bilirubin (mg/dL) | 0.2–1.3 | 2.51 ± 1.03 | 2.63 ± 1.11 | 1.29 ± 0.56 a | 1.52 ± 0.72b |
Direct bilirubin (mg/dL) | 0.1–0.5 | 0.78 ± 0.21 | 0.92 ± 0.14 | 0.41 ± 0.12 a | 0.63 ± 0.23b,c |
AST (U/L) | 17–59 | 49.38 ± 14.38 | 50.87 ± 17.51 | 44.19 ± 10.36 | 54.39 ± 21.28 |
ALT (U/L) | 21–72 | 43.33 ± 19.61 | 47.63 ± 23.03 | 50.29 ± 18.81 | 52.09 ± 24.11 |
INR | <3.9 | 1.25 ± 0.31 | 1.41 ± 0.43 | 1.97 ± 0.82 a | 2.24 ± 0.76b |
PTT | 25–28 | 41.37 ± 8.12 | 42.09 ± 6.39 | 40.82 ± 7.91 | 44.07 ± 8.73 |
BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; PTT, partial thromboplastin time. Results are expressed as mean ± standard deviation and a, b, c, p<0.05 is considered significant in Student’s t-test. I, II, III and IV represents group category.
I vs. III group,
II vs. IV group,
III vs. IV group.